PMID- 29804369
OWN - NLM
STAT- MEDLINE
DCOM- 20190329
LR  - 20211204
IS  - 1007-3418 (Print)
IS  - 1007-3418 (Linking)
VI  - 26
IP  - 1
DP  - 2018 Jan 20
TI  - [Research advances in the mammalian target of rapamycin signaling pathway and its 
      inhibitors in treatment of hepatocellular carcinoma].
PG  - 77-80
LID - 10.3760/cma.j.issn.1007-3418.2018.01.018 [doi]
AB  - Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase in the 
      downstream of the phosphatidylinositol 3-kinases (PI3K) family. This kinase plays 
      an important role in the development and progression of hepatocellular carcinoma 
      (HCC). Preclinical data demonstrate that 40%-50% of HCC patients have 
      dysregulated expression of the effectors of the mTOR signaling pathway, and the 
      activation of the mTOR pathway is associated with poorly differentiated tumors, 
      early tumor recurrence, and poor survival/prognosis. This article reviews the 
      research advances in the potential role of the mTOR signaling pathway and its 
      inhibitors in the treatment of HCC.
FAU - Li, S Z
AU  - Li SZ
AD  - Graduate School, Anhui Medical University, Hefei 230032, China.
FAU - Xu, F
AU  - Xu F
AD  - Beijing Institute of Radiation Medicine, State Key Laboratory of Proteomics, 
      National Center for Protein Sciences Beijing, Beijing Proteome Research Center, 
      National Engineering Research Center for Protein Drugs, Beijing 102206, China.
FAU - Sun, C Q
AU  - Sun CQ
AD  - Joint Center for Translational Medicine, Tianjin Baodi Hospital, Tianjin 301800, 
      China.
FAU - Xu, P
AU  - Xu P
AD  - Graduate School, Anhui Medical University, Hefei 230032, China; Beijing Institute 
      of Radiation Medicine, State Key Laboratory of Proteomics, National Center for 
      Protein Sciences Beijing, Beijing Proteome Research Center, National Engineering 
      Research Center for Protein Drugs, Beijing 102206, China.
LA  - chi
PT  - Journal Article
PT  - Review
PL  - China
TA  - Zhonghua Gan Zang Bing Za Zhi
JT  - Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of 
      hepatology
JID - 9710009
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Carcinoma, Hepatocellular/*drug therapy
MH  - Cell Line, Tumor
MH  - Humans
MH  - Liver Neoplasms/*drug therapy
MH  - Neoplasm Recurrence, Local
MH  - *Phosphatidylinositol 3-Kinases
MH  - *Proto-Oncogene Proteins c-akt
MH  - Sirolimus/*pharmacology
MH  - *TOR Serine-Threonine Kinases
OTO - NOTNLM
OT  - Carcinoma, hepatocellular
OT  - mTOR
OT  - mTOR inhibitors
OT  - mTOR signaling pathway
EDAT- 2018/05/29 06:00
MHDA- 2019/03/30 06:00
CRDT- 2018/05/28 06:00
PHST- 2018/05/28 06:00 [entrez]
PHST- 2018/05/29 06:00 [pubmed]
PHST- 2019/03/30 06:00 [medline]
AID - 10.3760/cma.j.issn.1007-3418.2018.01.018 [doi]
PST - ppublish
SO  - Zhonghua Gan Zang Bing Za Zhi. 2018 Jan 20;26(1):77-80. doi: 
      10.3760/cma.j.issn.1007-3418.2018.01.018.